ACE2 News and Research

RSS

Eris sublineage EG.5.1 can escape neutralizing antibodies better than other SARS-CoV-2 lineages

As a result of vaccination or infection, our immune system produces antibodies that attach to the spike protein of SARS-CoV-2, preventing the virus from entering and replicating within cells.

14 Sep 2023

Study characterizes SARS-CoV-2 Omicron BA.2.86: New variant under watch

Researchers identify a new SARS-CoV-2 variant, BA.2.86, with enhanced ability to evade immunity but lower infectivity compared to current variants. The study highlights the need for global monitoring due to its potential to become a predominant strain if it gains infectivity through mutations.

6 Sep 2023

Researchers characterize new SARS-CoV-2 BA.2.86 variant neutralization by monoclonal antibodies

Researchers used a SARS-CoV-2 spike protein-pseudotyped viral model to characterize BA.2.86 variant neutralization by monoclonal antibodies.

6 Sep 2023

Can SARS-CoV-2 infect poultry?

New research in the Virology Journal suggests that chickens could become intermediate hosts for newly emerged SARS-CoV-2 variants, posing a potential threat to public health. The study identifies AXL and ACE2 receptors in chickens as likely binding sites for the virus, highlighting the need for further research and preventive measures.

5 Sep 2023

SARS-CoV-2 Eris variant spreads faster and dodges immunity

Study investigates the characteristics of the EG.5.1 "Eris" variant of SARS-CoV-2, finding it more transmissible among hamsters and slightly better at evading immunity compared to the XBB.1.5 variant. The results suggest that these properties could be driving the variant's increasing prevalence in human populations.

5 Sep 2023

Study characterizes SARS-CoV-2 subvariants to inform development of next-generation COVID-19 vaccines

Researchers characterized two novel SARS-CoV-2 XBB variants, EG.5.1 and XBB.2.3.

4 Sep 2023

Study investigates the pathophysiological mechanisms of PASC after COVID-19

Researchers investigated early pathophysiological mechanisms potentially underlying PASC post-SARS-CoV-2 infection.

4 Sep 2023

Engineered ACE2 decoy shows promise as COVID-19 treatment

Researchers from Japan demonstrated that an engineered angiotensin-converting enzyme 2 (ACE2) receptor, which showed the potential to remarkably reduce the emergence of resistant virus strains, could successfully exert its therapeutic effect in primates, which may open avenues for the application of the technology for the treatment of humans.

30 Aug 2023

Unlocking ACE2: The enzyme that links COVID-19, heart disease, and diabetes

A recent study in the Journal of Biomedical Science examines the critical role of ACE2, an enzyme involved in blood volume and electrolyte balance, in chronic diseases like cardiovascular conditions, diabetes, and COVID-19. The research suggests that ACE2 could serve as both a disease severity biomarker and a therapeutic target.

28 Aug 2023

Differences in immune responses to IL-6 inhibition therapy between male and female COVID-19 patients

Researchers investigated whether anti‑interleukin 6 monoclonal antibodies were related to heterogenous treatment effects between male and female COVID-19 patients.

24 Aug 2023

How does COVID-19 influence your gut microbiota?

Researchers analyzed the fecal microbiota composition in COVID-19 patients in comparison to non-COVID-19 controls.

23 Aug 2023

A hybrid approach to re-engineer a SARS-CoV-1 neutralizing antibody against SARS-CoV-2

A hybrid approach involving a combination of conventional discovery and antibody repurposing to combat COVID-19.

21 Aug 2023

Proxalutamide shows promise as potential COVID-19 treatment

At the outset of the COVID pandemic, men appeared to suffer higher rates of severe illness and death, leading researchers to suspect a link between androgen receptors - which bind to hormones like testosterone--and SARS-CoV-2 viral infection.

18 Aug 2023

Study explores the protective effect of transmembrane mucins against SARS-CoV-2 infection

A recent study analyzed the role played by host mucins and mucin glycans with regard to SARS-CoV-2 entry into the airway epithelial cells.

15 Aug 2023

New insights into how coronaviruses invade cells

Unexpected new insights into how COVID-19 infects cells may help explain why coronaviruses are so good at jumping from species to species and will help scientists better predict how COVID-19 will evolve.

14 Aug 2023

The effectiveness of antimicrobial mouthwashes in reducing viral load in saliva of COVID-19 patients

Researchers assess the effectiveness of three types of mouthwash in reducing the viral load of SARS-CoV-2 in the saliva of infected individuals.

9 Aug 2023

Study finds that nose-picking may increase COVID-19 risk in health care workers

Researchers investigated whether physical and behavioral features among healthcare workers, e.g. nose picking, could increase the risk of SARS-CoV-2 infection.

8 Aug 2023

Study reports the first protein-based diagnostic signature to discriminate MIS-C from Kawasaki Disease and other common infections

Researchers explore the distinguishing features of MIS-C as compared to other inflammatory-infectious syndromes in children.

4 Aug 2023

What are the mediators linking cardiometabolic risk factors and severe COVID-19?

Researchers performed a genome-wide association study to explore whether biomarker levels are causally related to COVID-19 hospitalization.

2 Aug 2023

Intranasally administered SARS-CoV-2 RBD-based nanoparticle vaccine provides protection against lung pathology and viral load

In a recent study, researchers working at Ohio State University in the United States of America (USA) developed an intranasal subunit vaccine.